Page 1 | Search Results | Blood | American Society of Hematology

1-15 of 15

Sort by

Sort Order Select

Journal Articles

Real-World Treatment Patterns, Overall Survival, Healthcare Resource Utilization, and Costs Among U.S. Elderly Patients with Mantle Cell Lymphoma (MCL) after Failure of Covalent Btki Treatment

Patrick Squires, Justin T. Puckett, Katherine Elizabeth Ryland, Sachin Kamal-Bahl, Monika Raut, Jalpa A. Doshi, Scott F. Huntington

Blood (2023) 142 (Supplement 1): 2326.

https://doi.org/10.1182/blood-2023-181024

Published: 2023

Journal Articles

A Structured Literature Review Investigating the Current Treatment Landscape in Patients with Richter's Transformation (2011-2021)

Jennifer Prescott, Prabhakar Pandey, Adam Hall, Jyothsna Nathani, Rishabh Pandey, Katherine Elizabeth Ryland, Monika Raut, Patrick Squires

Blood (2022) 140 (Supplement 1): 12418–12420.

https://doi.org/10.1182/blood-2022-162230

Published: 2022

Journal Articles

Assessing the Epidemiology, Treatment Patterns, and Economic Impact of Marginal Zone Lymphoma: A Review of the Literature

Patrick Squires, Priyanka Saini, Prabhakar Pandey, Rishabh Pandey, Adam Hall, Katherine Elizabeth Ryland, Monika Raut, Jennifer Prescott

Blood (2022) 140 (Supplement 1): 11987–11989.

https://doi.org/10.1182/blood-2022-160070

Published: 2022

Journal Articles

Treatment Utilization Patterns, Health Resource Use, Costs, and Survival in Mantle Cell Lymphoma: A Real-World Analysis of a National Sample of Medicare Beneficiaries

Patrick Squires, Scott F. Huntington, Justin Puckett, Katherine Elizabeth Ryland, Sachin Kamal-Bahl, Monika Raut, Jalpa Doshi

Blood (2022) 140 (Supplement 1): 5041–5042.

https://doi.org/10.1182/blood-2022-158036

Published: 2022

Journal Articles

Diffuse Large B-Cell Lymphoma (DLBCL): A Structured Literature Review of the Epidemiology, Treatment Guidelines, and Real-World Treatment Patterns

Mahek Garg, Jitender Takyar, Arju Dhawan, Gurkiran Saggu, Neha Agrawal, Adam Hall, Monika Raut, Katherine Elizabeth Ryland

Blood (2022) 140 (Supplement 1): 12106–12107.

https://doi.org/10.1182/blood-2022-169045

Published: 2022

Journal Articles

Real-World Treatment Patterns, Healthcare Resource Use, and Costs Among Patients with Diffuse Large B-Cell Lymphoma: A Retrospective Analysis of US Claims Data

Mahek Garg, Ambika Satija, Yan Song, Eric Sarpong, Ben Meade, Esteban Lemus-Wirtz, Katherine Gaburo, James E. Signorovitch, Monika Raut, Katherine Elizabeth Ryland, Samhita Chakraborty

Blood (2022) 140 (Supplement 1): 5075–5076.

https://doi.org/10.1182/blood-2022-162730

Published: 2022

Journal Articles

Economic Burden and Treatment Patterns Among Patients with Mantle Cell Lymphoma in the US: A Retrospective Claims Analysis

Mahek Garg, Ambika Satija, Yan Song, Eric Sarpong, Ben Meade, Esteban Lemus-Wirtz, Katherine Gaburo, James E. Signorovitch, Monika Raut, Katherine Elizabeth Ryland, Samhita Chakraborty

Blood (2022) 140 (Supplement 1): 7920–7921.

https://doi.org/10.1182/blood-2022-162844

Published: 2022

Journal Articles

Real-World Treatment Patterns, Healthcare Resource Utilization, Costs, and Survival Among Medicare Beneficiaries with Diffuse Large B-Cell Lymphoma (DLBCL)

Mahek Garg, Scott F. Huntington, Justin Puckett, Sachin Kamal-Bahl, Monika Raut, Katherine Elizabeth Ryland, Jalpa Doshi

Blood (2022) 140 (Supplement 1): 10814–10815.

https://doi.org/10.1182/blood-2022-158026

Published: 2022

Journal Articles

Healthcare Resource Utilization and Cost in Patients with Relapsed/Refractory Classical Hodgkin's Lymphoma Who Received Autologous Stem Cell Transplantation in the US

Xiaoqin Yang, PhD, Kaushal D Desai, PhD MS, Adrienne M Gilligan, PhD, Monika Raut, Akash Nahar

Blood (2020) 136 (Supplement 1): 36–37.

https://doi.org/10.1182/blood-2020-136328

Published: 2020

Journal Articles

Real-World Conditional Survival Analysis of Patients with Relapsed/Refractory Classical Hodgkin's Lymphoma in the US

Kaushal D Desai, PhD MS, Xiaoqin Yang, PhD, Adrienne M Gilligan, PhD, Yeran Li, PhD, Monika Raut, Akash Nahar

Blood (2020) 136 (Supplement 1): 24–25.

https://doi.org/10.1182/blood-2020-136424

Published: 2020

Journal Articles

Effect of Pembrolizumab Monotherapy Versus Brentuximab Vedotin (BV) on Symptoms Associated with Health-Related Quality of Life (HRQoL) in Relapsed/Refractory (R/R) Classical Hodgkin Lymphoma (cHL) in the Randomized, Phase 3, Keynote-204 Study

Pier Luigi Zinzani, MD, Radhakrishnan Ramchandren, Armando Santoro, Ewa Paszkiewicz-Kozik, Robin Gasiorowski, Nathalie A Johnson, MD PhD, José S. R. de Oliveira, Valeria Buccheri, Guilherme Fleury Perini, Michael Dickinson, DMed Sci, Andrew McDonald, Muhit Ozcan, Naohiro Sekiguchi, Monika Raut, Hilde Giezek, Akash Nahar, John Kuruvilla, MD

Blood (2020) 136 (Supplement 1): 19–20.

https://doi.org/10.1182/blood-2020-139416

Published: 2020

Journal Articles

Healthcare Resource Utilization and Costs in Patients with Relapsed and Refractory Diffuse Large B-Cell Lymphoma: A U.S. Real-World Observational Study

Xiaoqin Yang, François Laliberté, Guillaume Germain, MSc, Monika Raut, Mei Sheng Duh, Shuvayu S Sen, Dominique Lejeune, Kaushal D Desai, Philippe Armand

Blood (2019) 134 (Supplement_1): 2133.

https://doi.org/10.1182/blood-2019-128368

Published: 2019

Journal Articles

Real-World Healthcare Resource Utilization in Patients with Classical Hodgkin Lymphoma Treated with Pembrolizumab and Nivolumab in the United States

François Laliberté, Monika Raut, Xiaoqin Yang, Guillaume Germain, MSc, Shuvayu S Sen, Sean D. MacKnight, Kaushal D Desai, Mei Sheng Duh

Blood (2019) 134 (Supplement_1): 4720.

https://doi.org/10.1182/blood-2019-128876

Published: 2019

Journal Articles

Patient-Reported Outcomes in Patients with Classical Hodgkin Lymphoma Treated with Pembrolizumab Monotherapy, Results of a Phase 2 Study

Bastian von Tresckow, Michelle A. Fanale, MD, Kirit M Ardeshna, MA MDFRCP FRCPath, Robert W. Chen, MD, Julia Meissner, MD, Franck Morschhauser, MD PhD, Craig H. Moskowitz, MD, Pier Luigi Zinzani, MD, Hilde Giezek, Arun Balakumaran, MD PhD, Monika Raut, PhD MS, Thao Vo, Pauline Brice, MD

Blood (2017) 130 (Supplement 1): 2169.

https://doi.org/10.1182/blood.V130.Suppl_1.2169.2169

Published: 2017

Journal Articles

Clinical Outcomes of Patients with 3 rd or Higher Relapsed Classical Hodgkin Lymphoma: Results from the German Hodgkin Study Group

Paul Broeckelmann, Horst Mueller, PhD, Esra Kücüksarioglan, Peter Kaskel, MD MBA, Veronika Metterlein, MPH, Hilde Giezek, MSc Biostatistics, Arun Balakumaran, MD PhD, Monika Raut, PhD MS, Andreas Engert, MD, Bastian von Tresckow

Blood (2017) 130 (Supplement 1): 2793.

https://doi.org/10.1182/blood.V130.Suppl_1.2793.2793

Published: 2017

NARROW

Real-World Treatment Patterns, Overall Survival, Healthcare Resource Utilization, and Costs Among U.S. Elderly Patients with Mantle Cell Lymphoma (MCL) after Failure of Covalent Btki Treatment

A Structured Literature Review Investigating the Current Treatment Landscape in Patients with Richter's Transformation (2011-2021)

Assessing the Epidemiology, Treatment Patterns, and Economic Impact of Marginal Zone Lymphoma: A Review of the Literature

Treatment Utilization Patterns, Health Resource Use, Costs, and Survival in Mantle Cell Lymphoma: A Real-World Analysis of a National Sample of Medicare Beneficiaries

Diffuse Large B-Cell Lymphoma (DLBCL): A Structured Literature Review of the Epidemiology, Treatment Guidelines, and Real-World Treatment Patterns

Real-World Treatment Patterns, Healthcare Resource Use, and Costs Among Patients with Diffuse Large B-Cell Lymphoma: A Retrospective Analysis of US Claims Data

Economic Burden and Treatment Patterns Among Patients with Mantle Cell Lymphoma in the US: A Retrospective Claims Analysis

Real-World Treatment Patterns, Healthcare Resource Utilization, Costs, and Survival Among Medicare Beneficiaries with Diffuse Large B-Cell Lymphoma (DLBCL)

Healthcare Resource Utilization and Cost in Patients with Relapsed/Refractory Classical Hodgkin's Lymphoma Who Received Autologous Stem Cell Transplantation in the US

Real-World Conditional Survival Analysis of Patients with Relapsed/Refractory Classical Hodgkin's Lymphoma in the US

Effect of Pembrolizumab Monotherapy Versus Brentuximab Vedotin (BV) on Symptoms Associated with Health-Related Quality of Life (HRQoL) in Relapsed/Refractory (R/R) Classical Hodgkin Lymphoma (cHL) in the Randomized, Phase 3, Keynote-204 Study

Healthcare Resource Utilization and Costs in Patients with Relapsed and Refractory Diffuse Large B-Cell Lymphoma: A U.S. Real-World Observational Study

Real-World Healthcare Resource Utilization in Patients with Classical Hodgkin Lymphoma Treated with Pembrolizumab and Nivolumab in the United States

Patient-Reported Outcomes in Patients with Classical Hodgkin Lymphoma Treated with Pembrolizumab Monotherapy, Results of a Phase 2 Study

Clinical Outcomes of Patients with 3 rd or Higher Relapsed Classical Hodgkin Lymphoma: Results from the German Hodgkin Study Group

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only